Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vertex pharmaceuticals (ireland) limited,ireland 28-32 pembroke street upper, d02 ek84 dublin 2 - ivacaftor; tezacaftor - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 100 mg/ 150 mg - ivacaftor 150mg; tezacaftor 100mg - ivacaftor and tezacaftor